CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The O3K project aims to create oral liquid formulations of Cyclophosphamide and Temozolomide for treating childhood cancers. By utilizing innovative NODS® technology, the project seeks to enhance drug delivery for infants and young children, ensuring better compliance and safety in paediatric oncology.
There is an urgent need for appropriate oral formulations of anticancer drugs for the treatment of paediatric malignancies in children.
The goal of the O3K consortium is to develop oral liquid formulations of Cyclophosphamide and Temozolomide, important chemotherapeutics which have been identified in the list of paediatric needs by EMEA (EMEA/197972/2007).
Both off-patent drugs are widely used orally for the treatment of childhood cancer.
However, the currently available tablets (Cyclophosphamid…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Newcastle Upon Tyne
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Milano
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Labège
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
